At #EADV this year, AbbVie is sharing late-breaking data on meaningful repigmentation improvements in non-segmental vitiligo. We’re excited to show the impact of continued responses over time. Learn more: https://bit.ly/47rLyZJ
About us
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
- Website
-
http://www.abbvie.com
External link for AbbVie
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- North Chicago, Illinois
- Type
- Public Company
- Specialties
- Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics, and Eye Care
Employees at AbbVie
View 60k employees at AbbVie
or
Locations
Updates
-
NEWS: We announced detailed results from our Phase 1 multiple ascending dose study of a long-acting amylin analog in adults being presented at this year's European Association for the Study of Diabetes e.V. (EASD) Annual Meeting. Learn more: https://bit.ly/4rJftpQ #EASD2026 [Video description: On-screen text reads, "Specialty News."]
-
At #EADV2026, we're showcasing new research from our robust dermatology portfolio that aims to help address unmet needs of patients. The data presented at EADV add to a growing evidence base and reflect our ongoing efforts to help advance care for patients across a broad range of immune-mediated skin conditions. Learn more about our work: https://abbv.ie/c9e4b8 [Video description: An animated video highlights AbbVie's commitment to dermatology care and the patient experience.]
-
NEWS: AbbVie is continuing to invest in AI as a driver of scientific innovation. Today, we announced a new partnership with Valkai to deploy purpose-built AI capabilities across targeted areas of clinical development, helping teams generate insights faster and improve efficiency. Learn more: https://bit.ly/4ylVNdU
-
-
Every person living with chronic lymphocytic leukemia (#CLL) has unique goals and lifestyle priorities. Open conversations between patients and their healthcare teams helps ensure their care plan reflects what matters most to them personally. Watch consultant hematologist Dr. Tal Munir and psychologist Prof. Amanda Kracen discuss why sharing personal preferences can have an impact on a patient’s treatment journey. [Video description: Dr. Tal Munir and Professor Amanda Kracen discuss the importance of shared decision-making] #BloodCancerAwareness #BCAM2026 #BeLeukemiaAware #WLD26
-
As cancer cases continue to rise globally, ensuring equitable access to innovative, personalized care is critical. We are focused on advancing insight-driven dialogue about the challenges facing cancer care to identify barriers, inform solutions and improve access to treatment. Explore key barriers impacting access to cancer care globally in Prescient's ONWARD (Oncology Needs, Workforce, Access, Research and Disparities) whitepaper, powered by The Dolon Institute and supported by AbbVie: https://lnkd.in/eT4yDDMX
-
According to the World Health Organization, 33% of people globally are impacted by a neurological disorder(1) — underscoring the need for continued awareness, support and advocacy. As the Official Pharmaceutical Sponsor of the PGA TOUR, AbbVie teed off Birdies for Brain Health at the 2026 Presidents Cup with a $330,000 donation to six patient advocacy organizations supporting people living with neurological and mental health conditions and their care partners. Our donation this year supports the important work led by American Migraine Foundation, National Headache Foundation, Mental Health America, NAMI, The Michael J. Fox Foundation for Parkinson's Research and Parkinson's Foundation. Learn more: abbvie.com/PGATOUR 1. World Health Organization. "Global status report on neurology." October 2025. Accessed Aug. 5, 2026. https://lnkd.in/eQf6aJsu
-
-
#Migraine is a debilitating neurological disease that affects over 1 billion people worldwide. This #MigraineAwarenessWeek, AbbVie is helping raise awareness of the disease’s impact and the need for greater recognition by sharing experiences from people like Antonia Cancino, who live with migraine: https://bbc.in/4iBUPFw [Video description: On-screen text reads: “I was conscious from a young age that I was different from my peers. I felt I had to work harder than my classmates to keep up in lessons because of the amount of school I missed. My brain felt foggy and I struggled to concentrate.”]
-
JUST IN: The European Commission has approved our treatment for active polyarticular juvenile idiopathic arthritis (#pJIA) in DMARD-IR patients two years of age and older. Learn more: https://bit.ly/4h7yej2 [Video description: On-screen text reads, “Immunology News.”]